Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.56 -1.4%	$4.10	$3.21 ▼ $8.06	$851.75M	0.59	4.52 million shs	3.48 million shs
NTLA Intellia Therapeutics	$9.20 -4.2%	$8.34	$5.90 ▼ $28.18	$952.96M	2.14	2.90 million shs	5.90 million shs
PAHC Phibro Animal Health	$23.88 -0.3%	$21.85	$16.16 ▼ $26.55	$967.95M	0.74	207,387 shs	247,450 shs
RNAC Cartesian Therapeutics	$9.76 -2.4%	$10.53	$8.46 ▼ $29.65	$253.31M	0.33	112,638 shs	79,818 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-1.39%	-1.11%	-10.78%	-30.60%	-40.17%
NTLA Intellia Therapeutics	-4.17%	+10.71%	0.00%	+2.22%	-62.90%
PAHC Phibro Animal Health	-0.33%	-0.21%	+2.71%	+9.04%	+36.61%
RNAC Cartesian Therapeutics	-2.40%	-6.33%	+5.17%	-39.19%	-55.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.076 of 5 stars	3.5	1.0	0.0	4.4	2.7	2.5	0.6
NTLA Intellia Therapeutics	4.4813 of 5 stars	4.3	1.0	0.0	4.7	2.9	2.5	0.6
PAHC Phibro Animal Health	3.8525 of 5 stars	0.8	4.0	2.5	1.1	2.8	3.3	2.5
RNAC Cartesian Therapeutics	1.4979 of 5 stars	3.4	0.0	0.0	0.0	1.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$10.89	205.87% Upside
NTLA Intellia Therapeutics	2.67	Moderate Buy	$34.95	279.89% Upside
PAHC Phibro Animal Health	1.67	Reduce	$20.80	-12.90% Downside
RNAC Cartesian Therapeutics	2.71	Moderate Buy	$43.00	340.57% Upside

Current Analyst Ratings Breakdown

Latest RNAC, ARDX, NTLA, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/12/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $45.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$333.61M	2.55	N/A	N/A	$0.73 per share	4.88
NTLA Intellia Therapeutics	$57.88M	16.46	N/A	N/A	$8.56 per share	1.07
PAHC Phibro Animal Health	$1.02B	0.95	$2.11 per share	11.30	$6.34 per share	3.77
RNAC Cartesian Therapeutics	$38.91M	6.51	N/A	N/A	($0.27) per share	-36.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	11.48	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	30.62	11.37	0.45	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	-510.72%	N/A	-7.01%	8/6/2025 (Estimated)

Latest RNAC, ARDX, NTLA, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.01%	N/A	61.54%	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest RNAC, ARDX, NTLA, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.04	4.12	3.81
NTLA Intellia Therapeutics	N/A	4.90	4.90
PAHC Phibro Animal Health	2.67	2.91	1.23
RNAC Cartesian Therapeutics	N/A	12.34	12.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
NTLA Intellia Therapeutics	88.77%
PAHC Phibro Animal Health	99.34%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
NTLA Intellia Therapeutics	3.10%
PAHC Phibro Animal Health	50.07%
RNAC Cartesian Therapeutics	60.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
RNAC Cartesian Therapeutics	64	25.95 million	10.30 million	Optionable

RNAC, ARDX, NTLA, and PAHC Headlines

Recent News About These Companies

We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate

June 21 at 8:01 PM | finance.yahoo.com

Cartesian Therapeutics holds annual stockholders meeting

June 18 at 12:12 AM | investing.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus PT from Analysts

June 17, 2025 | americanbankingnews.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 14, 2025 | marketbeat.com

Equities Analysts Offer Predictions for RNAC FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Cantor Fitzgerald Comments on RNAC FY2026 Earnings

June 10, 2025 | marketbeat.com

Nuveen Asset Management LLC Buys 47,889 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC)

June 5, 2025 | marketbeat.com

Cartesian Therapeutics Announces New Employment Inducement Grants

June 3, 2025 | globenewswire.com

BTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 2, 2025 | theglobeandmail.com

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 30, 2025 | globenewswire.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Lifted by Northern Trust Corp

May 28, 2025 | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for RNAC Earnings

May 23, 2025 | marketbeat.com

What is HC Wainwright's Forecast for RNAC Q1 Earnings?

May 22, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of "Moderate Buy" from Analysts

May 22, 2025 | marketbeat.com

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 13, 2025 | manilatimes.net

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 11, 2025 | finance.yahoo.com

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

May 5, 2025 | insidermonkey.com

Cartesian Therapeutics Announces New Employment Inducement Grants

May 2, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC, ARDX, NTLA, and PAHC Company Descriptions

Ardelyx NASDAQ:ARDX

$3.56 -0.05 (-1.39%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.59 +0.03 (+0.87%)

As of 06/20/2025 07:47 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Intellia Therapeutics NASDAQ:NTLA

$9.20 -0.40 (-4.17%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.22 +0.02 (+0.23%)

As of 06/20/2025 07:57 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$23.88 -0.08 (-0.33%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$23.89 +0.01 (+0.04%)

As of 06/20/2025 04:08 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Cartesian Therapeutics NASDAQ:RNAC

$9.76 -0.24 (-2.40%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.78 +0.03 (+0.26%)

As of 06/20/2025 04:04 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time